BRAF Gene and Melanoma: Back to the Future.

Autor: Ottaviano M; Department of Clinical Medicine and Surgery, Università Degli Studi di Napoli 'Federico II', 80131 Naples, Italy.; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy.; CRCTR Coordinating Rare Tumors Reference Center of Campania Region, 80131 Naples, Italy., Giunta EF; Department of Precision Medicine, Università Degli Studi della Campania Luigi Vanvitelli, 80131 Naples, Italy., Tortora M; CRCTR Coordinating Rare Tumors Reference Center of Campania Region, 80131 Naples, Italy., Curvietto M; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy., Attademo L; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy., Bosso D; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy., Cardalesi C; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy., Rosanova M; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy., De Placido P; Department of Clinical Medicine and Surgery, Università Degli Studi di Napoli 'Federico II', 80131 Naples, Italy., Pietroluongo E; Department of Clinical Medicine and Surgery, Università Degli Studi di Napoli 'Federico II', 80131 Naples, Italy., Riccio V; Department of Clinical Medicine and Surgery, Università Degli Studi di Napoli 'Federico II', 80131 Naples, Italy., Mucci B; Department of Clinical Medicine and Surgery, Università Degli Studi di Napoli 'Federico II', 80131 Naples, Italy., Parola S; Department of Clinical Medicine and Surgery, Università Degli Studi di Napoli 'Federico II', 80131 Naples, Italy., Vitale MG; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy., Palmieri G; CRCTR Coordinating Rare Tumors Reference Center of Campania Region, 80131 Naples, Italy., Daniele B; Oncology Unit, Ospedale del Mare, 80147 Naples, Italy., Simeone E; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy., On Behalf Of Scito Youth
Jazyk: angličtina
Zdroj: International journal of molecular sciences [Int J Mol Sci] 2021 Mar 27; Vol. 22 (7). Date of Electronic Publication: 2021 Mar 27.
DOI: 10.3390/ijms22073474
Abstrakt: As widely acknowledged, 40-50% of all melanoma patients harbour an activating BRAF mutation (mostly BRAF V600E). The identification of the RAS-RAF-MEK-ERK (MAP kinase) signalling pathway and its targeting has represented a valuable milestone for the advanced and, more recently, for the completely resected stage III and IV melanoma therapy management. However, despite progress in BRAF-mutant melanoma treatment, the two different approaches approved so far for metastatic disease, immunotherapy and BRAF+MEK inhibitors, allow a 5-year survival of no more than 60%, and most patients relapse during treatment due to acquired mechanisms of resistance. Deep insight into BRAF gene biology is fundamental to describe the acquired resistance mechanisms (primary and secondary) and to understand the molecular pathways that are now being investigated in preclinical and clinical studies with the aim of improving outcomes in BRAF-mutant patients.
Databáze: MEDLINE
Externí odkaz: